Drug shortages or anticipated problems with HIV medicine have not been identified.
The U.S. Food and Drug Administration (FDA) is closely monitoring the drug supply chain, as the COVID-19 pandemic has the potential to disrupt the supply of medical and pharmaceutical products in the United States.
The National Alliance of State and Territorial AIDS Directors (NASTAD) has also remained in contact with the major manufacturers of HIV medicine, as many of these products rely on ingredients produced in other countries.
As of January 26, 2021, there were no reports of manufacturing concerns or supply shortages of ART or PrEP.
Learn more about the FDA’s response to COVID-19external icon.